ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS supplies an all‑in‑one platform of clinical‑grade induced pluripotent stem cells (iPSCs), next‑generation mRNA reprogramming tools, and contract development and manufacturing services focused on immuno‑oncology cell therapies. Their cGMP‑compliant iPSC lines and banks provide long‑term safety, performance stability, and traceable, clinic‑ready cell sources for developers. The company also offers genome‑editing, scalable manufacturing, and regulatory‑focused quality systems to accelerate therapeutic development.
Funding
Funding not disclosed
Founders
Product
Problem
Developing immuno‑oncology cell therapies requires reliable, clinical‑grade induced pluripotent stem cells (iPSCs), precise genome editing, and scalable manufacturing under cGMP conditions. Accessing all of these capabilities from separate vendors creates delays, regulatory risk, and high operational complexity.
Solution
Allele Biotechnology and Pharmaceuticals offers an integrated platform that combines next‑generation mRNA reprogramming, GMP‑compliant iPSC line and bank production, precision genome editing, and a full‑spectrum CDMO service focused on iPSC‑based cell therapies. The platform provides end‑to‑end support from custom or off‑the‑shelf iPSC sourcing through cell line development, expansion, banking, and quality control, to technology transfer and large‑scale manufacturing. By consolidating these functions under a single cGMP‑qualified facility, Allele reduces development timelines, ensures regulatory‑ready cell sources, and enables flexible scaling for both client‑driven and proprietary workflows.
Target Audience
Primary customers are biotech and pharmaceutical companies developing iPSC‑based immuno‑oncology cell therapies, including both early‑stage innovators seeking custom cell lines and established firms requiring scalable manufacturing and regulatory support.
Features
- Next‑gen mRNA reprogramming that delivers fast, clean, and efficient conversion of somatic cells to iPSCs
- GMP‑certified iPSC lines and banks with long‑term stability, safety profiling, and traceability
- Precision genome editing (including CRISPR) optimized for iPSC safety and therapeutic readiness
- cGMP expansion, single‑cell cloning, and banking services ensuring consistent, clinic‑ready cell material
- Full‑spectrum CDMO offering process development, tech‑transfer, scale‑up/scale‑out manufacturing, and quality assurance under rigorous cGMP, QMS, and analytical validation frameworks
- Flexible service models supporting custom line development, off‑the‑shelf products, and autologous iPSC partnerships
- Integrated quality control pipelines, including karyotyping, endotoxin testing, and release criteria aligned with regulatory expectations